| Item Type | Name |
|
Concept
|
Combined Modality Therapy
|
|
Concept
|
Drug Therapy
|
|
Concept
|
Drug Therapy, Combination
|
|
Concept
|
Therapeutic Equivalency
|
|
Concept
|
Salvage Therapy
|
|
Concept
|
Treatment Outcome
|
|
Concept
|
Neoadjuvant Therapy
|
|
Concept
|
Molecular Targeted Therapy
|
|
Academic Article
|
Pathologic findings and outcomes for octogenarians presenting with uterine malignancy.
|
|
Academic Article
|
Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence.
|
|
Academic Article
|
Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion.
|
|
Academic Article
|
Outcomes of cervical cancer and positive para-aortic lymph nodes in the modern era of chemoradiation.
|
|
Academic Article
|
Treatment Advances in Locoregionally Advanced and Stage IVB/Recurrent Cervical Cancer: Can We Agree That More Is Not Always Better?
|
|
Academic Article
|
A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors.
|
|
Academic Article
|
Applying a computer-aided scheme to detect a new radiographic image marker for prediction of chemotherapy outcome.
|
|
Academic Article
|
Contribution of age to clinical trial enrollment and tolerance with ovarian cancer.
|
|
Academic Article
|
The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.
|
|
Academic Article
|
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.
|
|
Academic Article
|
Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer.
|
|
Academic Article
|
Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes.
|
|
Academic Article
|
Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
|
|
Academic Article
|
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
|
|
Academic Article
|
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
|
|
Academic Article
|
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
|
|
Academic Article
|
Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.
|
|
Academic Article
|
Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis.
|
|
Academic Article
|
A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.
|
|
Academic Article
|
Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer.
|
|
Academic Article
|
Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
|
|
Academic Article
|
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
|
|
Academic Article
|
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies.
|
|
Academic Article
|
Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy.
|
|
Academic Article
|
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
|
|
Academic Article
|
Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes.
|
|
Academic Article
|
Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population?
|
|
Academic Article
|
A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors.
|
|
Academic Article
|
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
|
|
Grant
|
Targeting HPV Consequences in a Cervical Cancer Clinical Trial
|
|
Grant
|
Lead Academic Participating Site for the Development and Conduct of NCTN Trials
|
|
Academic Article
|
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
|
|
Academic Article
|
PARP inhibitor associated treatment related myeloid neoplasms: What was a "Rare" complication may be less so.
|
|
Academic Article
|
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
|
|
Academic Article
|
Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.
|
|
Academic Article
|
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
|